The U.S. Food and Drug Administration (FDA) granted approval for a generic version of dapagliflozin on April 6, 2026. This approval, designated as Abbreviated New Drug Application (ANDA) 211545, was for a product sponsored by ALKEM LABS LTD., introducing a new generic option to the market.
Background
An Abbreviated New Drug Application (ANDA) approval indicates that a generic drug is bioequivalent to its reference listed drug. This means it works in the same way and provides the same clinical benefit. Generic drugs typically offer a cost-effective alternative to brand-name medications, increasing patient access.
What this means
The approval of a generic dapagliflozin product by ALKEM LABS LTD. is expected to enhance competition within the pharmaceutical market. This development can lead to greater availability and potentially lower prices for medications containing dapagliflozin, benefiting patients and healthcare systems.
Source
The information regarding this approval was obtained from the U.S. Food and Drug Administration (FDA) through its official database of approved drug products. The approval for ANDA 211545 for dapagliflozin was recorded on April 6, 2026, and is publicly accessible on accessdata.fda.gov.